Atea Pharmaceuticals Inc AVIR

Healthcare

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

NDAQ:AVIR - Post by User

Atea Pharmaceuticals Inc

<< Previous

Bullboard Posts

Post by AviseAnalyticson Nov 19, 2021 6:43am

147 Views

Post# 34144436

6 REASONS TO AVOID ATEA PHARMACEUTICALS ($AVIR)

https://www.aviseanalytics.com/6-reasons-to-avoid-atea-pharmaceuticals/

Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the termination of its strategic collaboration with Roche, for the joint development of AT-527, intended for the treatment of COVID-19.

The news comes on the heels of the candidate failing a Phase 2 trial named MOONSONG, in patients with mild or moderate cases of COVID-19.

Learn More:

Learn More

<< Previous

Bullboard Posts

Theralase advances cancer research after private placement